This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Anti-vascular endothelial growth factor for the management of peripapillary choroidal neovascular membrane.
Eye (London, England) · 2026
Latest funding
- $596,700
Focused Ultrasound for Vitreous Hemorrhage: Preclinical Evaluation of Safety, Efficacy, and Mechanism of Action
CIHR · 2025 · Nominated PI
1 publications.
Anti-vascular endothelial growth factor for the management of peripapillary choroidal neovascular membrane.
Hanna A, Sriranganathan A, Kertes P, Yau G, Sharma R
Focused Ultrasound for Vitreous Hemorrhage: Preclinical Evaluation of Safety, Efficacy, and Mechanism of Action
Principal investigators: Yau, Gary
Keywords: Commercialization; Focused Ultrasound; Medical Device; Vitreous Hemorrhage
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.